(Q37955222)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22077480%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

title

Gemcitabine-loaded innovative nanocarriers vs GEMZAR: biodistribution, pharmacokinetic features and in vivo antitumor activity (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22077480%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

1 reference

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22077480%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Donatella Paolino

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22077480%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Massimo Fresta

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22077480%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

author name string

Christian Celia

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22077480%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

language of work or name

English

0 references

publication date

5 November 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22077480%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Drug Delivery

16 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22077480%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

volume

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22077480%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22077480%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

page(s)

1609-1629

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22077480%20AND%20SRC:MED&resulttype=core&format=json

Ochratoxin A from a toxicological perspective

16 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.632630

Environmental and chemical carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.632630

Anticancer activity of a broccoli derivative, sulforaphane, in barrett adenocarcinoma: potential use in chemoprevention and as adjuvant in chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.632630

Resveratrol and cellular mechanisms of cancer prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.632630

Anti-proliferative effects of simocyclinone D8 (SD8), a novel catalytic inhibitor of topoisomerase II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.632630

BPR0C261 is a novel orally active antitumor agent with antimitotic and anti-angiogenic activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.632630

3-Arylisoquinolines as novel topoisomerase I inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.632630

Gemcitabine: progress in the treatment of pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.632630

Phase I trial and pharmacokinetics of gemcitabine in children with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.632630

The influence of the schedule and the dose of gemcitabine on the anti-tumour efficacy in experimental human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.632630

Schedule-dependent therapeutic efficacy of the combination of gemcitabine and cisplatin in head and neck cancer xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.632630

Cellular pharmacology of gemcitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.632630

Pharmacogenomics of gemcitabine: can genetic studies lead to tailor-made therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.632630

CNT1 expression influences proliferation and chemosensitivity in drug-resistant pancreatic cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.632630

Collateral sensitivity to gemcitabine (2',2'-difluorodeoxycytidine) and cytosine arabinoside of daunorubicin- and VM-26-resistant variants of human small cell lung cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.632630

Determinants of resistance to 2',2'-difluorodeoxycytidine (gemcitabine).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.632630

Improved in vitro anti-tumoral activity, intracellular uptake and apoptotic induction of gemcitabine-loaded pegylated unilamellar liposomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.632630

Liposomal delivery improves the growth-inhibitory and apoptotic activity of low doses of gemcitabine in multiple myeloma cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.632630

Cytotoxic effects of gemcitabine-loaded liposomes in human anaplastic thyroid carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.632630

In vivo activity of gemcitabine-loaded PEGylated small unilamellar liposomes against pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.632630

Gemcitabine-loaded PEGylated unilamellar liposomes vs GEMZAR: biodistribution, pharmacokinetic features and in vivo antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.632630

Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.632630

Liposome-enabled synergistic interaction of antimicrobial agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.632630

Simultaneous modulation of multidrug resistance and antiapoptotic cellular defense by MDR1 and BCL-2 targeted antisense oligonucleotides enhances the anticancer efficacy of doxorubicin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.632630

In vitro and in vivo characterization of doxorubicin and vincristine coencapsulated within liposomes through use of transition metal ion complexation and pH gradient loading

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.632630

Drug ratio-dependent antitumor activity of irinotecan and cisplatin combinations in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.632630

Safety, pharmacokinetics, and efficacy of CPX-1 liposome injection in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.632630

Drug delivery systems for differential release in combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.632630

Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.632630

Pharmacokinetic consequences of pegylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.632630

The carrier potential of liposomes in biology and medicine (second of two parts)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.632630

Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.632630

Recent advances with liposomes as pharmaceutical carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.632630

The size of liposomes: a factor which affects their targeting efficiency to tumors and therapeutic activity of liposomal antitumor drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.632630

Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.632630

Liposomes as delivery systems for nasal vaccination: strategies and outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.632630

Rapid and sustained response of an intra- and extracranial large cell lymphoma mass to liposomal intrathecal Ara-C and R-MegaCEOP systemic chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.632630

Novel approaches to deliver gemcitabine to cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.632630

Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing lipophilic gemcitabine prodrugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.632630

New-concept chemotherapy by nanoparticles of biodegradable polymers: where are we now?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.632630

Antitumoral activity of PEG-gemcitabine prodrugs targeted by folic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.632630

Polyaspartylhydrazide copolymer-based supramolecular vesicular aggregates as delivery devices for anticancer drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.632630

A phase I clinical, plasma, and cellular pharmacology study of gemcitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.632630

Antitumor activity of EGFR targeted pH-sensitive immunoliposomes encapsulating gemcitabine in A549 xenograft nude mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.632630

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.632630

Biodegradable polymersomes loaded with both paclitaxel and doxorubicin permeate and shrink tumors, inducing apoptosis in proportion to accumulated drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.632630

Folate-targeted supramolecular vesicular aggregates based on polyaspartyl-hydrazide copolymers for the selective delivery of antitumoral drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.632630

A new liposomal formulation of Gemcitabine is active in an orthotopic mouse model of pancreatic cancer accessible to bioluminescence imaging.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.632630

Influence of the macromolecular architecture on the self-assembly of amphiphilic copolymers based on poly(N,N-dimethylamino-2-ethyl methacrylate) and poly(epsilon-caprolactone).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.632630

Squalene: A natural triterpene for use in disease management and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.632630

Characterization of lipophilic gemcitabine prodrug-liposomal membrane interaction by differential scanning calorimetry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.632630

Squalenoyl nanomedicines as potential therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.632630

Discovery of new hexagonal supramolecular nanostructures formed by squalenoylation of an anticancer nucleoside analogue

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.632630

A new nanomedicine of gemcitabine displays enhanced anticancer activity in sensitive and resistant leukemia types

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.632630

Transport of nucleoside analogs across the plasma membrane: a clue to understanding drug-induced cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.632630

Expression of nucleoside transporters, deoxycitidine kinase, ribonucleotide reductase regulatory subunits, and gemcitabine catabolic enzymes in primary ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.632630

Adenoviral-mediated overexpression of human equilibrative nucleoside transporter 1 (hENT1) enhances gemcitabine response in human pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.632630

Equilibrative nucleoside transporter 1 genotype, cytidine deaminase activity and age predict gemcitabine plasma clearance in patients with solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.632630

The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.632630

Transmembrane diffusion of gemcitabine by a nanoparticulate squalenoyl prodrug: an original drug delivery pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.632630

Carboxypeptidases cathepsins X and B display distinct protein profile in human cells and tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.632630

Squalenoylation favorably modifies the in vivo pharmacokinetics and biodistribution of gemcitabine in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.632630

Preclinical toxicology (subacute and acute) and efficacy of a new squalenoyl gemcitabine anticancer nanomedicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.632630

Freeze-drying of squalenoylated nucleoside analogue nanoparticles

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.632630

Anticancer efficacy of squalenoyl gemcitabine nanomedicine on 60 human tumor cell panel and on experimental tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.632630

Encapsulation of gemcitabine lipophilic derivatives into polycyanoacrylate nanospheres and nanocapsules

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.632630

Preparation of albumin nanospheres loaded with gemcitabine and their cytotoxicity against BXPC-3 cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.632630

Preparation, physicochemical characterization and cytotoxicity in vitro of gemcitabine-loaded PEG-PDLLA nanovesicles

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.632630

A novel animal model to evaluate the ability of a drug delivery system to promote the passage through the BBB.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.632630

Antitumor effects of polysorbate-80 coated gemcitabine polybutylcyanoacrylate nanoparticles in vitro and its pharmacodynamics in vivo on C6 glioma cells of a brain tumor model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.632630

Translocation of poly(ethylene glycol-co-hexadecyl)cyanoacrylate nanoparticles into rat brain endothelial cells: role of apolipoproteins in receptor-mediated endocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.632630

Superior preclinical efficacy of gemcitabine developed as chitosan nanoparticulate system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.632630

Impact of S-1 on the survival of patients with advanced pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.632630

Synergistic cytotoxicity and molecular interaction on drug targets of sorafenib and gemcitabine in human pancreas cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.632630

Chemo-radiotherapy in non-small cell lung cancer: the role of gemcitabine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.632630

Effectiveness of bevacizumab- and pemetrexed-cisplatin treatment for patients with advanced non-squamous non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.632630

Cisplatin-gemcitabine therapy in metastatic breast cancer: Improved outcome in triple negative breast cancer patients compared to non-triple negative patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.632630

Gemcitabine plus Paclitaxel versus Paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.632630

Pharmacokinetic study to optimize the intravesical administration of gemcitabine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.632630